Organoids Market Report 2025

The organoids market size has grown exponentially in recent years. It will grow from $3.98 billion in 2024 to $4.83 billion in 2025 at a compound annual growth rate (CAGR) of 21.3%. The growth in the historic period can be attributed to biomedical research advances, drug discovery and development needs, disease modeling requirements, personalized medicine trends, and regulatory support.

The organoids market size is expected to see exponential growth in the next few years. It will grow to $10.82 billion in 2029 at a compound annual growth rate (CAGR) of 22.3%. The growth in the forecast period can be attributed to the increased prevalence of chronic diseases, advancements in genome editing techniques, rise in stem cell research, collaborations and partnerships, and clinical translation efforts. Major trends in the forecast period include application in regenerative medicine, in vivo imaging techniques, collaborations for multi-organoid systems, ethical and legal considerations, commercialization and market expansion.

An increase in the incidence and prevalence of chronic and infectious diseases is expected to drive the growth of the organoid market in the future. Chronic diseases are conditions that persist for over a year and require continuous medical care. Organoids are utilized to investigate various chronic diseases and their treatments, as they provide immediate and reliable insights into pathogen biology and drug screening. Thus, the rise in the incidence and prevalence of these diseases will bolster the organoid market. For example, in June 2024, the National Health Service, a publicly funded healthcare system in the UK, reported that 3,615,330 individuals registered with a GP were diagnosed with non-diabetic hyperglycemia, or pre-diabetes, in 2023, up from 3,065,825 in 2022, representing an increase of nearly 18%. Therefore, the growing prevalence of chronic diseases is expected to propel the organoid market.

The escalating number of clinical trials aimed at drug development is set to fuel the expansion of the organoid market. These trials, totaling 452,604 globally as of May 17, 2023, registered on ClinicalTrials.gov - an increase from over 365,000 trials in early 2021, underscore the growing utilization of organoids. Leveraged in modeling diseases and refining personalized medicine, organoids play a pivotal role in advancing scientific understanding and improving patient care, solidifying their contribution to market growth.

Technological advancements stand as a prominent trend shaping the organoid market. Companies within this sector continuously introduce cutting-edge technologies to fortify their market positions. Notably, in March 2023, MIMETAS unveiled the OrganoReady product line featuring a novel adult stem cell-derived tubular organoid, harnessing innovative technology for mechanistic toxicology and drug-induced organ injury assessments. Developed on the patented microfluidic platform, OrganoPlate, these perfused 3D structures demonstrate the industry's commitment to pioneering advancements in organoid technologies.

Market leaders prioritize the development of pioneering platforms such as organoid panel screening, driving progress in preclinical oncology drug discovery. For example, in November 2023, Crown Bioscience launched OrganoidXplore, a revolutionary large-scale organoid panel screening platform. Utilizing their AR organoid technology, this platform streamlines preclinical drug discovery by offering reliable drug response comparisons that faithfully replicate original tumors' genomic, morphological, and pathophysiological characteristics. With enhanced performance and cost-effectiveness, OrganoidXplore signals a significant stride in accelerating oncology drug discovery.

In December 2022, Molecular Devices LLC, a UK-based research and development company, acquired Cellesce Ltd. for an undisclosed amount. The acquisition will provide Molecular Devices LLC with Cellesce Ltd human-derived cell or organoid lines and strengthen the company's position as a 3D biology solutions innovator. Cellesce Ltd is a UK-based company with expertise in cell expansion focused on organoids.

Major companies operating in the organoids market include Cellesce Ltd., STEMCELL Technologies, HUB Organoids, DefiniGEN, 3Dnamics Inc., OcellO B.V., Organoid Therapeutics, PeproTech Inc., QGel SA, Corning Incorporated, Thermo Fisher Scientific, Trevigen Inc., Path BioAnalytics, R&D Systems, Merck KGaA, 3D BioMatrix Inc., 3D Biotek LLC, AMS Biotechnology (Europe) Limited, Greiner Bio-One, 3-D Matrix, InSphero AG, Synthego Corporation, Axol Bioscience Ltd., TissUse GmbH, CytoSMART Technologies BV, EMD Millipore Corporation, Epithelix Sàrl.

North America was the largest region in the organoids market in 2024. Asia-pacific is expected to be the fastest-growing region in the global organoids market size forecast period. The regions covered in the organoids market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the organoids market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Organoids, intricate three-dimensional tissue cultures derived from stem cells, serve as invaluable assets in tailored regenerative medicine, gene repair, and transplantation therapy.

These organoids come in various forms such as hepatic, colorectal, and intestinal, among others. Hepatic organoids, for instance, represent fully functional in vitro models of the liver. They play a pivotal role in addressing an array of research queries related to hepatic development, regeneration, and disease modeling. These groundbreaking tools harness different sources, including pluripotent stem cells and organ-specific adult stem cells. They find application across developmental biology, infectious disease pathology, regenerative medicine, drug efficacy and toxicity testing, as well as drug discovery and personalized medicine. Their adoption spans a wide spectrum, encompassing hospitals, diagnostic centers, biotechnology and pharmaceutical companies, and other industries seeking to leverage their immense potential for advancements in healthcare and research.

The organoids market research report is one of a series of new reports that provides organoids market statistics, including organoids industry global market size, regional shares, competitors with a organoids market share, detailed organoids market segments, market trends, and opportunities, and any further data you may need to thrive in the organoids industry. This organoids market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The organoids market consists of sales of epithelial organoid, embryonic organoid, and cerebral organoid. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.